www.who.int/news-room/fact-sheets/detail/dementia. Accessed 20 Sep 2022.

GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019, 18, 88–106.

Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert MO, Nordberg A, Blennow K, Galasko D, Stern Y, Rowe CC, Salloway S, Schneider LS, Cummings JL, Feldman HH (2021) Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol 20:484–496

Article  CAS  PubMed  PubMed Central  Google Scholar 

Norwitz NG, Mota AS, Norwitz SG, Clarke K (2019) Multi-loop model of Alzheimer disease: an integrated perspective on the Wnt/GSK3β, α-synuclein, and type 3 diabetes hypotheses. Front Aging Neurosci 11:184

Article  CAS  PubMed  PubMed Central  Google Scholar 

De la Monte SM, Tong M (2014) Brain metabolic dysfunction at the core of Alzheimer’s disease. Biochem Pharmacol 88:548–559

Article  PubMed  Google Scholar 

De la Monte SM (2014) Type 3 diabetes is sporadic Alzheimers disease: mini-review. Eur Neuropsychopharmacol 24:1954–1960

Article  PubMed  PubMed Central  Google Scholar 

Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monteet SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease -is this type 3 diabetes? J Alzheimers Dis 7:63–80

Article  CAS  PubMed  Google Scholar 

Bosco D, Fava A, Plastino M, Montalcini T, Pujia A (2011) Possible implications of insulin resistance and glucose metabolism in Alzheimer’s disease pathogenesis. J Cell Mol Med 15:1807–1821

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology 53:1937–1942

Article  CAS  PubMed  Google Scholar 

Crane PK, Walker R, Hubbard RA, Li G, Nathan DM, Zheng H, Haneuse S, Craft S, Montine TJ, Kahn SE, McCormick W, McCurry SM, Bowen JD, Larson EB (2013) Glucose levels and risk of dementia. N Engl J Med 369:540–548

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alvarez E, Martínez MD, Roncero I, Chowen JA, García-Cuartero B, Gispert JD, Sanz C, Vázquez P, Maldonado A, De Cáceres J, Desco M, Pozo MA, Blázquez E (2005) The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 92:798–806

Article  CAS  PubMed  Google Scholar 

Reich N, Hölscher C (2022) The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review. Front Neurosci 16:970925

Article  PubMed  PubMed Central  Google Scholar 

Zhou M, Chen S, Peng P, Gu Z, Yu J, Zhao G, Deng Y (2019) Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3β. Biochem Biophys Res Commun 511:154–160

Article  CAS  PubMed  Google Scholar 

Viles-Olmos IA, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T (2013) Exenatide and the treatment of patients with Parkinson’s disease. J Clin Invest 123:2730–2736

Article  Google Scholar 

Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T (2014) Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease. J Parkinsons Dis 4(3):337–344

Article  CAS  PubMed  Google Scholar 

Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K (2017) Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390:1664–1675

Article  CAS  PubMed  PubMed Central  Google Scholar 

Athauda D, Gulyani S, Karnati HK, Li Y, Tweedie D, Mustapic M, Chawla S, Chowdhury K, Skene SS, Greig NH, Kapogiannis D, Foltynie T (2019) Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with parkinson disease: a secondary analysis of the exenatide-PD trial. JAMA Neurol 76(4):420–429

Article  PubMed  PubMed Central  Google Scholar 

Gejl M, Gjedde A, Egefjord L, Møller A, Hansen SB, Vang K, Rodell A, Brændgaard H, Gottrup H, Schacht A, Møller N, Brock B, Rungby J (2016) In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci 8:108

Article  PubMed  PubMed Central  Google Scholar 

Gejl M, Brock B, Egefjord L, Vang K, Rungby J, Gjedde A (2017) Blood-brain glucose transfer in Alzheimer’s disease: effect of GLP-1 analog treatment. Sci Rep 7:17490

Article  PubMed  PubMed Central  Google Scholar 

Watson KT, Wroolie TE, Tong G, Foland-Ross LC, Frangou S, Singh M, McIntyre RS, Roat-Shumway S, Myoraku A, Reiss AL, Rasgon NL (2019) Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease. Behav Brain Res 356:271–278

Article  CAS  PubMed  Google Scholar 

Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Int Med 256:183–194

Article  CAS  Google Scholar 

Measso G, Cavarzeran F, Zappalà G, Lebowitz BD, Crook TH, Pirozzolo FJ, Amaducci LA, Massari D, Grigoletto F (1993) The mini-mental state examination: Normative study of an Italian random sample. Dev Neuropsychol 9:77–85

Article  Google Scholar 

American Diabetes Association (2013) Diagnosis and classification of diabetes mellitus. Diabetes Care 36(Suppl. 1):S67–S74

Article  Google Scholar 

Rosen WG (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141(11):1356–1364

Article  CAS  PubMed  Google Scholar 

Magni E, Binetti G, Padovani A, Cappa SF, Bianchetti A, Trabucchi M (1996) The Mini-Mental State Examination in Alzheimer’s disease and multi-infarct dementia. Int Psychogeriatr 8(1):127–134

Article  CAS  PubMed  Google Scholar 

Caffarra P, Gardini S, Dieci F, Copelli S, Maset L, Concari L, Farina E, Grossi E (2013) The qualitative scoring MMSE pentagon test (QSPT): a new method for differentiating dementia with Lewy Body from Alzheimer’s disease. Behav Neurol 27(2):213–220

Article  PubMed  PubMed Central  Google Scholar 

Carlesimo GA, Caltagirone C, Gainotti G (1996) The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur Neurol 36(6):378–384

Article  CAS  PubMed  Google Scholar 

Novelli G, Papagno C, Capitani E et al (1986) Three clinical tests for the assessment of lexical retrieval and production. Norms from 320 normal subjects. Arch Psicol Neurol Psichiatr 47(4):477–506

Google Scholar 

Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO (1983) Development and validation of a geriatric depression screening scale: a preliminary report. J Psych Res 17:37–49

Article  CAS  Google Scholar 

Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566–572

Article  CAS  PubMed  Google Scholar 

Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308–2314

Article  CAS  PubMed  Google Scholar 

Derouesné C, Thibault S, Lozeron P, Baudouin-Madec V, Piquard A, Lacomblez L (2002) Perturbations of activities of daily living in Alzheimer’s disease. A study of 172 patients with the using a questionnaire completed by caregivers. Rev Neurol (Paris). 158:684–700

PubMed  Google Scholar 

Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9(3):179–186

Article  CAS  PubMed  Google Scholar 

10.5281/zenodo.10069131

Yaribeygi H, Rashidy-Pour A, Atkin SL, Jamialahmadi T, Sahebkar A (2021) GLP-1 mimetics and cognition. Life Sci 264:118645

Article  CAS  PubMed  Google Scholar 

Lerche S, Brock B, Rungby J, Bøtker HE, Møller N, Rodell A, Bibby BM, Holst JJ, Schmitz O, Gjedde A (2008) Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans. Diabetes 57:325–331

Article  CAS  PubMed  Google Scholar 

Mullins RJ, Mustapic M, Chia CW, Carlson O, Gulyani S, Tran J, Li Y, Mattson MP, Resnick S, Egan JM, Greig NH, Kapogiannis D (2019) A Pilot Study of Exenatide Actions in Alzheimer’s Disease. Curr Alzheimer Res 16:741–752

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nørgaard CH, Friedrich S, Hansen CT, Gerds T, Ballard C, Møller DV, Knudsen LB, Kvist K, Zinman B, Holm E, Torp-Pedersen C, Mørch LS (2022) Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimers Dement (N Y) 8(1):e12268

Article  PubMed